Gale Pharmaceutical-B(01672) reported the latest breakthrough research on the first-in-class fatty acid synthase (FASN) inhibitor diniprosta (ASC40) for the treatment of acne at the 2025 European Academy of Dermatology and Venereology (EADV) Annual Congress.

Zhijong Finance APP news, Ge Li Pharmaceutical-B (01672) announced that at the 2025 European Academy of Dermatology and Venereology (EADV) annual meeting held in Paris, France on September 17, 2025, the latest breakthrough research on the oral presentation of denifanstat (ASC40) in the treatment of moderate to severe acne vulgaris in Phase III study (NCT06192264) was reported.